PulseAGGREGATOR

Feed Stories Sources Features FAQs

PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Your news command center for 10,000+ sources. Search, filter, and set alerts — then cut through the noise with bias analysis, story clustering, and blindspot detection.

PR Newswire Energy

prCenter

2h ago

Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipientstranslating…

First participant dosed in Phase 2 RENGEVITY-201 study evaluating pegrizeprument (VEL-101) in kidney transplant recipients Pegrizeprument is being developed as a novel maintenance immunosuppressive therapy for the prevention of organ rejection in transplant recipients This…

Factuality

73/100

Political Bias

Center

Ownership

PR Press Group

Country

Unknown

Keywords#Transplant Recipients#Pegrizeprument#Kidney Transplant#Organ Rejection#Phase

Read Original ↗

Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients | Pulse Aggregator